Latest news

Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe

Debiopharm International SA and EORTC announce a collaboration to investigate Triptorelin for treatment of Salivary Gland Cancers

Debiopharm International SA and Arbor Pharmaceuticals, LLC announce their US commercialization partnership for Triptorelin in Central Precocious Puberty

United Laboratories Inc. and Debiopharm International SA announce the launch of Pamorelin® LA in the Philippines

Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP)

Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada

Orient EuroPharma and Debiopharm Group™ announce their partnership and the launch of Pamorelin LA in Singapore

Debiopharm Group™ Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty

Dr. Reddy’s launches Debiopharm’s Pamorelin® LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer